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Summary Three hundred and sixty-seven women presenting to the Breast Unit at Guy's Hospital between 1975 and 1990 whose first distant
metastasis was in the skeleton were identified and the influence of a number of patient and tumour characteristics on the development and
subsequent prognosis of bone metastases was assessed.
One hundred and thirty-nine women had disease that remained clinically confined to the skeleton. They were more likely to be older, with
lobular carcinoma and to have presented initially with little or no axillary lymph node involvement. The 228 women who subsequently
developed disease at extra-osseus sites were more likely to have poorly differentiated ductal tumours and heavy lymph node involvement at
primary diagnosis.
On multivariate analysis, the clinical and pathological factors of greatest prognostic importance for survival after the development of
bone metastases were histological grade (P = < 0.0001), oestrogen receptor status (P = < 0.0001), bone disease at initial presentation
(P= < 0.0001), disease-free interval (P= 0.002) and age (P= 0.006).
To enable a rational cost-effective use of bisphosphonates in
metastatic bone disease, selection ofpatients with relatively indo-
lent, bone-only disease for bisphosphonate therapy (as defined in
this study) should be compared with the current licensed recom-
mendation of unselected treatment for all patients with lytic bone
metastases.
Bone metastases are frequent in advanced breast cancer and
often contribute to the cause ofdeath. Like breast cancer affecting
other organs, metastatic bone disease has an extremely variable
prognosis. The median survival is 2 years with 20% of patients
remaining alive for 5 years after first recurrence in bone (Coleman
andRubens, 1987). In addition, a significant proportion ofpatients
appear clinically to have disease confined to the skeleton, and
these women die of the complications of metastatic bone disease,
namely immobility, pathological fractures, hypercalcaemia of
malignancy and bone marrow failure, with no evidence clinically
ofinvolvement at other metastatic sites.
With the development ofbisphosphonates as specific treatments
for metastatic bone disease (Body et al, 1996), there is increased
interest in identifying those patients who are most likely to benefit
from bisphosphonate treatment. In addition, ifprophylactic use of
bisphosphonates proves able to influence the development ofbone
metastases, it will beimportant toidentify those patients at greatest
risk of bone involvement, particularly in isolation from other
metastatic disease, so that treatment can be targeted rationally.
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In this study, we have reviewed the clinical and tumour charac-
teristics of patients developing first recurrence of breast cancer in
bone and identifiedprognostic factors thatpredict forboth survival
and/or subsequent spread to other metastatic sites.
PATIENTS AND METHODS
Three hundred and sixty-seven women presenting to the Breast
Unit at Guy's Hospital between 1975 and 1990 whose first distant
metastasis was in the skeleton were identified from the database.
This database contains information on patient and tumour charac-
teristics, a number of biological features, such as histological
grade and steroid receptor status, details of metastatic involve-
ment, response to treatment and survival.
Histological grading was performed almost entirely by one
pathologist using the Bloom and Richardson grading (Bloom and
Richardson, 1957). Oestrogen and progesterone receptor status
were measured during this time period using the dextran-coated
charcoal method as described by King et al (1979).
Clinical management followed consistent guidelines throughout
the study period. All patients were assessed clinically on a regular
basis, and bone scans, radiographs of regions of increased uptake
and chest radiographs were performed whenever a change in
systemic therapy was indicated. Routine liver scans were not
performed unless there was clinical evidence of hepatomegaly or
disordered serum tests of liver function. Brain scans were only
performed for investigation ofspecific symptoms.
Endocrine therapy has been the initial treatment of choice for
symptomatic advanced breast cancer. For premenopausal patients,
this has been ovarian ablation ± prednisolone and, for post-
menopausal patients, tamoxifen ± prednisolone. The only excep-
tions to this policy have been those known to have oestrogen-
and progesterone-negative tumours or the occasional patient with
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Table 1 Patient and tumour characteristics for the study population, those with disease remaining confined to the skeleton (bone
only) and those subsequently developing metastases at other sites (bone and other)
Total Bone only Bone and other
population (Bo) (B*)
(n = 367) (n = 139) (n = 228) P-value
Mean age (years) 55.94 59.23 53.95 < 0.001
Menstrual status
Pre 118 (32) 33 (24) 85 (37) 0.009
Post 185 (50) 88 (63) 97 (43) 0.0002
Peri 55 (15) 17 (12) 38 (17) NS
Other/unknown 9 (2) 1 (1) 8 (4) NS
T size
Mean 4.47 4.39 4.53 NS
Range 0-19 0-11 0-19
Nodal status
Negative 80 (22) 40 (29) 40 (18) 0.02
1-3 Positive 77 (21) 34 (24) 43 (19) NS
> 4 Positive 92 (25) 22 (16) 70 (30) 0.001
Unknown 118 (32) 43 (31) 75 (33) NS
Histology/grade
Ductal grade 1 6 (2) 3 (2) 3 (1) NS
Ductal grade 2 140 (38) 54 (39) 86 (38) NS
Ductal grade 3 100 (29) 27 (19) 73 (32) 0.001
Lobular 57 (16) 29 (21) 28 (12) 0.04
Other/unknown 64 (17) 26 (19) 38 (17) NS
Receptor status
ER + 238 (65) 96 (69) 142 (62) NS
ER- 67 (18) 20 (14) 47 (21) NS
ER unknown 62 (17) 23 (17) 39 (17) NS
PR + 162 (44) 66 (47) 96 (42) NS
PR - 123 (34) 42 (30) 81 (36) NS
PR unknown 82 (22) 31 (22) 51 (22) NS
NS, not significant; ER, oestrogen receptor; PgR, progesterone receptor. Numbers in parentheses are percentages.
Table 2 Frequency of major complications of skeletal involvement.
Hypercalcaemia of malignancy 70 (19%)
Pathological fracture of a long bone 68 (19%)
Spinal cord compression 36 (10%)
Bone marrow failure/leucoerythroblastic anaemia 33 (9%)
0 3 6 9
Time (years)
Figure 1 Time from initial presentation of breast
of bone metastases
For the purpose of statistical analysis, survival curves were
calculated using the method of Kaplan and Meier (1958), with
_n = 356 significance determined using the log-rank test (Peto et al, 1977).
12 15 18 Multivariate survival analysis was performed using Cox's propor-
tional hazards model (Cox, 1972). Relative risks and associated
cancer to the development confidence intervals (CIs) were calculated from the proportional
hazards regression coefficients. To enable all patients to be
included in the multivariate analyses, missing values were re-
coded to equal the median value forthat variable, and an additional
immediately life-threatening additional visceral disease, mainly
affecting the liver. In these circumstances, chemotherapy has been
preferred. The only major change in treatment policy has been
increased use of adjuvant systemic treatment, principally for
patients with axillary node-positive tumours (since the early 1980s).
Since the mid 1980s patients with bone metastases may have been
given bisphosphonate treatment in the context of a number of clin-
ical trials. Throughout this time, radiotherapy has been used as the
treatment ofchoice for palliation oflocal bone pain.
dummy variable was also included to code for 'missing' vs 'not
missing' for that variable. None of these dummy variables were
significant in the analyses.
RESULTS
The patient and tumour characteristics for the study population
(n = 367) are shown in Table 1. The mean age was 56 years with a
range of23-85 years. Table 1 also shows the characteristics of 139
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Table 3 Univariate and multivariate results for prognostic variables assessed by Cox proportional hazards model
Variable" Univariate Multivariate
P-value RR 95% Cl P-value RR 95% Cl
Age (years) (< 70 vs .70) 0.004 1.65 1.2-2.3 0.006 1.67 1.2-2.4
Menstrual status (Pre vs Post) 0.02 1.34 1.05-1.7 0.02 1.36 1.1-1.8
Histologyb (Ductal grade) <0.0001 1.82 1.4-2.3 <0.0001 1.75 1.4-2.2
ER status (+ve vs -ve) < 0.0001 2.11 1.6-2.8 <0.0001 1.99 1.5-2.7
DFI (.3 years vs < 3 years) 0.002 1.71 1.3-2.3 0.002 1.62 1.2-2.2
Bone disease at presentation (yes vs no) 0.04 1.47 1.0-2.2 < 0.0001 2.65 1.7-4.0
Stage at presentation (I/ll vs III/IV) 0.02 1.34 1.1-1.7 0.02 1.40 1.1-1.9
RR, relative risk; Cl, confidence interval; DFI, disease-free interval; ER, oestrogen receptor. aGroup listed first has better survival. bNon-ductal histologies
included with ductal grade 2. Ductal grade is 1, 2 or 3. Grades 1 and 2 compared with 2 and 3. To compare 1 with 3 would be RR2.
Chi = 31.43
P < 0.001
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Figure 2 Survival after first recurrence in the skeleton according to
histological grade and type. n = 6, Grade 1 ductal; n = 139, grade 2 ductal;
n = 100, grade 3 ductal; n = 57, lobular; n = 54, other/unknown
Figure 4 Survival after first recurrence in the skeleton according to
disease-free interval (DFI) between initial presentation and development of
bone metastases. n = 243, DFI < 3 years; n = 112, DFI 3 years
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Figure 3 Survival after first recurrence in the skeleton according to
oestrogen receptor (ER) status. +ve, positive ER status; -ve, negative ER
status
patients with disease remaining confined to the skeleton (BO) and
the 228 subsequently developing metastases at non-osseus sites
(B+). Bo patients were more likely at diagnosis to be older, post-
menopausal women with lobular carcinoma and less likely to have
poorly differentiated ductal grade III tumours. Patients with Bo
disease were also more likely to have presented initially with little
or no involvement of axillary lymph nodes. Patients with four or
more positive axillary lymph nodes, in addition to generally
having a poor prognosis, were more likely to develop disease
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Figure 5 Survival after first recurrence in the skeleton according to
subsequent development of non-osseus metastases (B+) or disease confined
to the skeleton (Bo). Yes, bone and other subsequent sites (B+); no, bone
only (BO)
outside the skeleton (B+). There was no difference in oestrogen or
progesterone receptor status between BO and B+ patients.
Figure 1 shows the time from diagnosis ofbreast cancer to first
recurrence in the skeleton with a median time to bone metastases
of 18 months. Thirty patients (8%) had received adjuvant
endocrine treatment and 59 (16%) adjuvant chemotherapy. Forty-
three B+ patients (19%) received adjuvant chemotherapy compared
with only 16 (11%) of Bo patients, reflecting the nodal involve-
ment of the B+ patients. However, this difference did not reach
statistical significance.
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Figure 6 Survival after first recurrence in the skele
subsequent development of liver metastases (yes, n
confined to the skeleton (no, n = 259)
Table 2 shows the frequency of major
skeletal involvement. Hypercalcaemia and pz
a long bone (principally femora or humeri) M
complications, each occurring in a little ur
There was no significant difference in the fr
tions between patients with Bo or those with
The probability of survival after develol
was assessed according to the available
biological characteristics using the Cox
model. The variables tested along with both
variate prognostic significance are shown in
Patients having bone disease coincident M
tation of their breast cancer [disease-free in
40] had a better survival than other patients.
more marked on multivariate than univariat
the influence ofadditional features expected
nosis, notably worse histology, older age a
interval (by definition). Histological grade a
most significant prognostic factor with gi
tumours or lobular carcinoma having the be
III the worst survival (Figure 2). Oestrogen
also predicted survival with ER-positive pati
than those who were ER-negative (Figure 3)
Survival from the diagnosis ofbone metas
disease-free interval from breast cancer di
Figure 4. Patients with a disease-free interva
(n = 112) had a better survival than thosi
interval of less than 3 years (n = 243, P = 0.0
development of bone metastases was
premenopausal patients then for those wor
peri-menopausal or post-menopausal (P = 0.'
Patients with Bo disease had a median
compared with 1.6 years in B+ patients (P =I
difference was most apparent for those X
developing metastases in the liver (Figure 6)
The stepwise multivariate analysis was re
patients. The factors predicting for survival
the same in both groups, although because o:
some factors now just failed to reach st,
However, in the Bo group, all relative risks w
that the prognostic factors are more predic
bone-only disease.
DISCUSSION
Chi= 19.18 Patients with bone metastases may experience a protracted clinical
P< 0.001 course as a result ofboth the indolent nature ofthe disease and the
remissions obtained by systemic treatment. Patients with disease
remaining confined to the skeleton (BO) have a better prognosis than
the patients who develop metastatic disease at non-osseus sites (B+).
Elderly post-menopausal patients were more likely to have Bo
disease than those who were pre- or peri-menopausal. Disease
remaining confined to the skeleton was more likely with lobular
No n= 259 carcinomas and less so with poorly differentiated grade III ductal
10 12 tumours. Similar to previous studies (Coleman and Rubens, 1987;
Koenders et al, 1991), oestrogen receptor status predicted for the
development ofbone metastases, but it was not important in deter-
mining the patients in whom metastatic disease would remain clin- ton according to ically confined to the skeleton. In recent years, a number ofstudies
have indicated a relationship between tumour expression of
parathyroid hormone-related peptide (PTHrP) and the develop-
ment ofbone metastases (Bundred et al, 1992; Vargas et al, 1992).
complications from Unfortunately, it was not possible to retrospectively assess the
athological fracture of tumours in this series for PTHrP expression.
vere the most frequent The observation that tumours with little or no axillary lymph
ider 20% of patients. node involvement are more likely to remain confined to the
*equency of complica- skeleton is interesting. Bone metastases are typically distributed to
B+ disease patterns. the axial skeleton, and anatomical factors are thought to contribute
ping bone metastases to this, with a possibility of passage of malignant cells from the
clinical, tumour and breast specifically to the axial bone marrow circulation through
proportional hazards Batson's low-pressure valveless vertebral-venous plexus (Scher
iunivariate and multi- and Yagoda, 1987). In patients with heavy lymph node involve-
Table 3. ment, the pattern of vascular invasion or capability of malignant
vith the initial presen- cells to survive in the circulation may be different, predisposing to
lterval (DF1) = 0; n = a more widespread pattern of metastases.
This observation was As expected, histological and biological features that indicate a
:e analysis because of more aggressive tumour phenotype predict for a poor prognosis.
to confer a poor prog- Those patients with a short disease-free interval, and presumably a
md short disease-free more rapidly growing tumour, have a worse prognosis than those
mnd type was the next who are either poorly differentiated or of oestrogen/progesterone
rade I and II ductal receptor-negative status. The only exception to this was the subgroup
!st survival and grade of40 patients whose initial presentation was complicated by the pres-
receptor (ER) status ence of bone metastases. Despite having no disease-free interval,
ients surviving longer adverse histological features and being of older age, these patients
did particularly well and presumably represent a distinct subgroup of
,tases according to the patients with metastatic bone disease who deserve further study.
iagnosis is shown in Major complications related to bone metastases develop in only
1 ofmore than 3 years a minority ofpatients, prompting speculation, particularly in those
e with a disease-free with disease apparently confined to the skeleton, of their mode of
02). Survival after the death. Presumably immobility due to pain and large doses of
slightly better for narcotic analgesics predispose the patient to infection, particularly
nen who were either pneumonia.
002). The bisphosphonates, notably intravenous pamidronate (Purohit
survival of 2.1 years et al, 1994; Conte et al, 1996; Hortobagyi et al, 1996) and to a lesser
0.001, Figure 5). This extent oral clodronate (Paterson et al, 1993), have been shown to
patients subsequently relieve pain, reduce analgesic consumption and improve mobility.
As a result, they could be reasonably expected, particularly in those
Xpeated for Bo and B+ with bone-only disease, to have a positive impact on survival as well
Lremained essentially as quality of life. To date, the preliminary analyses of placebo-
f the smaller numbers controlled studies have failed to show any influence of bisphospho-
atistical significance. nate treatment on survival (Paterson et al, 1993; Hortobagyi et al,
iere higher, indicating 1996). However, none of the randomized studies conducted to date
vtive in patients with have attempted to select those patients who are most likely to benefit
from bisphosphonates, notably those with bone-only disease.
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Both pamidronate and clodronate are relatively expensive drugs
andbecause ofincreasing pressure onhealth carebudgets, despitethe
impressive clinical trial results, cannot be immediately incorporated
into routine long-term supportive treatment for all patients with bone
metastases. Until better biological or biochemical predictors of
response to bisphosphonates are available (Vinholes et al, 1996), we
would suggest that only those patients with a relatively good prog-
nosis should be selected forlong-term bisphosphonate treatment. On
the basis ofthe data presented, this would include bone-only disease
after a long DFI from either a steroid receptor-positive and/or
favourable histology tumour. Support for such selection does
however require analysis of a larger database of patients, with
recording of skeletal events and their subsequent treatment. It is
hoped that the recent randomized trials ofpamidronate (Hortobagyi
et al, 1996; Lipton et al, 1997), which included the collection ofdata
for economic evaluation as well as meticulous recording of skeletal
events, will use these data for analysis not only by treatment group
but also according to prognostic factors, including those identified in
this study, to assess whether the selective use of bisphosphonates
improves the cost-effectiveness of this new treatment modality. In
addition, andpossibly ofgreatervalue, mightbe the ability to specify
those patients at most risk of developing serious complications of
bone metastases, particularly pathological fracture and hyper-
calcaemia, but the relevantpredictors remain to be identified.
ACKNOWLEDGEMENTS
We are grateful to Dr W Gregory for statistical advice, Dr RR
Millis for the histological grading of tumours, Dr RJ King for
steroid receptor status and the data management staff and medical
personnel in the ICRF Clinical Oncology Unit at Guy's Hospital
for producing and maintaining the clinical database.
REFERENCES
Bloom HJG and Richardson WW (1957) Histological grading and prognosis in
breast cancer: a study of 1409 cases ofwhich 359 have been followed for 15
years. BrJ Cancer 2: 359-377
Body J-J, Coleman RE and Piccart M (1996) Use ofbisphosphonates in cancer
patients. Cancer Treat Rev 22: 265-287
Bundred NJ, Walker RA, Ratcliffe WA, Warwick J, Morrison JM and Ratcliffe JG
(1992) Parathyroid hormone related protein and skeletal morbidity in breast
cancer. EurJ Cancer 28: 690-692
Coleman RE and Rubens RD (1987) The clinical course ofbone metastases. BrJ
Cancer55: 61-66
Conte PF, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G
and Ford JM (1996) Delay in progression ofbone metastases treated with
intravenous pamidronate: results from a multicentre randomised controlled
trial. J Clin Oncol 14: 2552-2559
Cox DR (1972) Regression models and life tables. JR Stat Soc B 34: 187-220
Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, SinoffC, Wheeler H,
Simeone JF, Seaman J, KnightRD, Heffernan M and Reitsma D (1996)
Efficacy ofpamidronate in reducing skeletal complications in patients with
breast cancer and lytic bone metastases. New Engl JMed335: 1785-1791
Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete
observations. Am StatAssoc J53: 457-481
King RJB, Redgrave R, Hayward JL, Millis RR and Rubens RD (1979) The
measurement ofreceptors for oestradiol and progesterone in human breast
cancers. In SteroidReceptorAssays In Breast Tumours: Methodological and
clinical aspects, King RJB. (ed.), p. 55. Alpha Omega: Cardiff
Koenders PG, Beex LVAM, Langens R, Kloppenborg PWC, Smals AGH, Benraad J
for the Breast Cancer Study Group (1991) Steroid hormone receptor activity of
primary human breast cancer and pattern offirst metastasis. Breast CancerRes
Treat 18: 27-32
Lipton A, Theriault R, LeffR, Gluck S, Stewart J, Costello S, Simeone J, Seaman J,
Knight R, Heffeman M and Reitsma D (1997) Long-term reduction ofskeletal
complications in breast cancer patients with osteolytic bone metastases
receiving hormone therapy, by monthly 90 mg pamidronate (Aredia) infusions.
ASCO Proc 16: 152a
Paterson AHG, Powles TJ, Kanis JA, McClosky E, Hanson J and Ashley S (1993)
Double blind controlled trial ofclodronate in patients with bone metastases
from breast cancer. JClin Oncol 11: 59-65
Peto R, Pike MC and Armitage P (1977) Design and analysis ofclinical trials
requiring prolonged observation ofeach patient. II. Analysis and examples.
BrJCancer35: 1-39
Purohit OP, Anthony C, Radstone CR, Owen J and Coleman RE (1994) High-dose
intravenous pamidronate for metastatic bone pain. BrJ Cancer70: 554-558
Scher HI and Yagoda A (1987) Bone metastases: Pathogenesis, treatment and
rationale for use ofresorption inhibitors. Am JMed82 (suppl. 2a): 6-27
Vargas SJ, Gillespie MT, Powell GJ, Southby GJ, Donks JA, Moseley JM and Martin
TJ (1992) Localisation ofparathyroid hormone-related protein mRNA
expression in breast cancer and metastatic lesions by in situ hybridisation.
JBone Miner Res 7: 971-979
Vinholes J, Coleman RE and Eastell R (1996) Effects ofbone metastases on bone
metabolism. Implications for diagnosis, imaging and assessment ofresponse to
cancer treatment. Cancer TreatRev 22: 289-331
British Journal ofCancer (1998) 77(2), 336-340 @ CancerResearch Campaign 1998